Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 2Classical hematology 1

Conditions

Lymphoma, Mantle-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 12Cyclosporine 11Radiotherapy 10Tacrolimus 9fludarabine phosphate 8Mycophenolic Acid 8Busulfan 8Antilymphocyte Serum 8Methylprednisolone 7Melphalan 7Peripheral Blood Stem Cell Transplantation 6Methotrexate 6Filgrastim 6Cord Blood Stem Cell Transplantation 6Whole-Body Irradiation 5Thiotepa 2Sirolimus 2visilizumab 1thymoglobulin 1merphos 1itacitinib 1fludarabine 1Vorinostat 1Transplantation 1Therapeutics 1Stem Cell Transplantation 1RFT5-SMPT-dgA immunotoxin 1Methylprednisolone Hemisuccinate 1Methylprednisolone Acetate 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Graft vs Host Disease × Calcineurin Inhibitors × Classical hematology × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡